Three years of qualification
Audited Supplier
In This Store
Benepure Pharmaceutical co., Ltd, originated in 2004 and headquartered in china(Sichuan) Free Trade Area is a professional manufacturer and research institution, serving the pharmaceutical, veterinary, cosmetics, natural foods and animal nutrition industries by providing a diverse range of over 300 unique beneficial ingredients. Based on quality first, Benepure focuses on R&D and technology innovation, and insists sustainable development strategy to unify eco-environmental protection, social benefits, customers and enterprise benefits. Benepure's researchers and analysts come from diverse backgrounds in food processing, chemistry,biochemistry and pharmacy sectors, inwhich over 15% specialized staffs engaged in research and development work.5o far, more than 90% personnel in R&D team hold Certificates of Master's Degree and specialized researchers make it possible to driveBenepure's research and development. With high quality system, cutting-edge technologies, highly qualified professionals, strict safety standards, and the most up-to-date equipment. Benepure is able to have a wide range of chemical synthesis reaction technology and all-round plant extract technology to provide high-quality and competitive products. Benepure has ISO, KOSHER, HACCP, HALAL and other certifications. Main products: Citrus Aurantium L. Extracts: Diosmin, Hesperidin, Naringin, etc., Sophora Japonica L. Extracts: Rutin, troxrutin, etc., other advantageous products include: soybean isoflavone, puerarin, vitamin B2, berberine hydrochloride, lutein, tea extract, protective amino acid series products.
Year of Establishment: 2014
Total Assets(USD):
Total Number of Staff: 50-100
Main Competitive Advantages: Brand Name,Production Capacity,Buyers' Specifications Accepted,Reputation,Quality Service
Other Competitive Advantages: Customized solutions.
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094
Follow Us：
Pharma Sources Insight January 2025
